Could a new drug combo keep aggressive prostate cancer in check?
NCT ID NCT03263650
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This study looks at whether the drug olaparib, taken after initial chemotherapy, can help control aggressive variant prostate cancer (AVPC) for longer. About 96 men will receive cabazitaxel, carboplatin, and prednisone first, then either olaparib or observation. The goal is to see if olaparib delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.